Nurix Therapeutics suffered its worst one-day loss as a public company when Sanofi terminated development of the Phase I immunology candidate SAR448272 (NX-3911). This program was a key part of their nearly seven-year collaboration worth up to $2.5 billion to develop protein degradation drugs.
Despite the termination, the collaboration continues. The trial for SAR448272 had started in Germany and was set to expand into other European countries. Sanofi had previously made a $10 million payment to Nurix for this program.
Nurix stated that its cash runway would not be affected, maintaining enough funds to operate into the second half of 2029. However, investors reacted negatively, leading to a 38% drop in Nurix’s stock price.
Sanofi’s decision to halt the program was attributed to emerging nonclinical findings, though specific details were not disclosed. Nurix has not reviewed the data that led to this decision.
Source: genengnews.com · Image: Lab fights Ebola 141206-A-MK740-105 by Sgt. Ange Desinor, Public domain, via Wikimedia Commons
Open the full market picture for your next decision →
